Success Metrics

Clinical Success Rate
84.8%

Based on 289 completed trials

Completion Rate
85%(289/341)
Active Trials
19(4%)
Results Posted
22%(64 trials)
Terminated
52(11%)

Phase Distribution

Ph phase_2
215
47%
Ph phase_3
109
24%
Ph early_phase_1
2
0%
Ph not_applicable
48
10%
Ph phase_1
75
16%
Ph phase_4
3
1%

Phase Distribution

77

Early Stage

215

Mid Stage

112

Late Stage

Phase Distribution452 total trials
Early Phase 1First-in-human
2(0.4%)
Phase 1Safety & dosage
75(16.6%)
Phase 2Efficacy & side effects
215(47.6%)
Phase 3Large-scale testing
109(24.1%)
Phase 4Post-market surveillance
3(0.7%)
N/ANon-phased studies
48(10.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.5%

289 of 359 finished

Non-Completion Rate

19.5%

70 ended early

Currently Active

19

trials recruiting

Total Trials

459

all time

Status Distribution
Active(20)
Completed(289)
Terminated(70)
Other(80)

Detailed Status

Completed289
unknown78
Terminated52
Withdrawn18
Active, not recruiting11
Recruiting8

Development Timeline

Analytics

Development Status

Total Trials
459
Active
19
Success Rate
84.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (0.4%)
Phase 175 (16.6%)
Phase 2215 (47.6%)
Phase 3109 (24.1%)
Phase 43 (0.7%)
N/A48 (10.6%)

Trials by Status

suspended20%
unknown7817%
terminated5211%
not_yet_recruiting10%
withdrawn184%
active_not_recruiting112%
recruiting82%
completed28963%

Recent Activity

Clinical Trials (459)

Showing 20 of 459 trialsScroll for more
NCT03784326Phase 2

Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma

Active Not Recruiting
NCT03161522Phase 2

Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

Recruiting
NCT03609216Phase 2

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

Active Not Recruiting
NCT04729959Phase 2

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

Active Not Recruiting
NCT04221438Phase 2

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

Terminated
NCT02366819Phase 4

Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Suspended
NCT00379340Phase 3

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

Active Not Recruiting
NCT06347796Not Applicable

Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study

Recruiting
NCT02701153Not Applicable

Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort

Recruiting
NCT01334021Phase 2

Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer

Active Not Recruiting
NCT04243005Not Applicable

Supramarginal Resection in Glioblastoma

Active Not Recruiting
NCT00003042Phase 2

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

Completed
NCT04675710Phase 2

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

Active Not Recruiting
NCT00335816Phase 2

Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

Active Not Recruiting
NCT03750227Phase 3

Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors

Recruiting
NCT06211504Phase 4

Sinus Tarsi Implant as an Adjuvant Procedure to Medial Displacement Calcaneal Osteotomy in the Treatment of Mobile Adult Acquired Flatfoot Deformity

Recruiting
NCT00077285Phase 2

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Active Not Recruiting
NCT06908824Not Applicable

No Endotamponade for Macular Hole Repair: the NEMAR Study

Recruiting
NCT06622421Not Applicable

Piezoeletric Surgery vs Conventional Surgery for Treatment of MRONJ

Not Yet Recruiting
NCT02467738Early Phase 1

Surgical Resection and Intraoperative Cesium-131 Brachytherapy for Head and Neck Cancer

Completed

Drug Details

Intervention Type
PROCEDURE
Total Trials
459